-
EP3004082
European procedure
Extract from the Register of European Patents
EP About this file: EP3004082
| EP3004082 - CXCR7 RECEPTOR MODULATORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 08.06.2018 Database last updated on 15.06.2024 | |
| Former | The patent has been granted Status updated on 30.06.2017 | ||
| Former | Grant of patent is intended Status updated on 02.02.2017 | Most recent event Tooltip | 17.07.2020 | Lapse of the patent in a contracting state New state(s): AL | published on 19.08.2020 [2020/34] | Applicant(s) | For all designated states Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91 4123 Allschwil / CH | [2017/30] |
| Former [2016/15] | For all designated states Actelion Pharmaceuticals Ltd. Gewerbestrasse 16 4123 Allschwil / CH | Inventor(s) | 01 /
FRETZ, Heinz c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil / CH | 02 /
GUERRY, Philippe c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil / CH | 03 /
KIMMERLIN, Thierry c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil / CH | 04 /
LEHEMBRE, Francois c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil / CH | 05 /
POTHIER, Julien c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil / CH | 06 /
SIENDT, Hervé c/o Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil / CH | 07 /
VALDENAIRE, Anja Starenstrasse 12 CH-4059 Basel / CH | [2016/15] | Representative(s) | Velker, Jörg, et al c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91 4123 Allschwil / CH | [N/P] |
| Former [2016/15] | Velker, Jörg Actelion Pharmaceuticals Ltd Gewerbestrasse 16 4123 Allschwil / CH | Application number, filing date | 14730591.6 | 28.05.2014 | [2016/15] | WO2014IB61774 | Priority number, date | WO2013IB54478 | 30.05.2013 Original published format: PCT/IB2013/054478 | [2016/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014191929 | Date: | 04.12.2014 | Language: | EN | [2014/49] | Type: | A1 Application with search report | No.: | EP3004082 | Date: | 13.04.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.12.2014 takes the place of the publication of the European patent application. | [2016/15] | Type: | B1 Patent specification | No.: | EP3004082 | Date: | 02.08.2017 | Language: | EN | [2017/31] | Search report(s) | International search report - published on: | EP | 04.12.2014 | Classification | IPC: | C07D405/12, C07D211/56, A61K31/455 | [2016/15] | CPC: |
C07D217/04 (EP,US);
A61P29/00 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/06 (EP);
A61P43/00 (EP);
C07D211/56 (EP,US);
C07D217/06 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/15] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | CXCR7-REZEPTORMODULATOREN | [2016/15] | English: | CXCR7 RECEPTOR MODULATORS | [2016/15] | French: | MODULATEURS DU RÉCEPTEUR DE CXCR7 | [2016/15] | Entry into regional phase | 04.01.2016 | National basic fee paid | 04.01.2016 | Designation fee(s) paid | 04.01.2016 | Examination fee paid | Examination procedure | 04.01.2016 | Examination requested [2016/15] | 18.07.2016 | Amendment by applicant (claims and/or description) | 03.02.2017 | Communication of intention to grant the patent | 01.06.2017 | Fee for grant paid | 01.06.2017 | Fee for publishing/printing paid | 01.06.2017 | Receipt of the translation of the claim(s) | Opposition(s) | 03.05.2018 | No opposition filed within time limit [2018/28] | Fees paid | Renewal fee | 30.03.2016 | Renewal fee patent year 03 | 23.05.2017 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 02.08.2017 | MK | 02.08.2017 | RS | 02.08.2017 | SM | 02.08.2017 | [2020/34] |
| Former [2020/31] | MK | 02.08.2017 | |
| RS | 02.08.2017 | ||
| SM | 02.08.2017 | ||
| Former [2018/27] | RS | 02.08.2017 | |
| SM | 02.08.2017 | ||
| Former [2018/11] | RS | 02.08.2017 | Cited in | International search | [I]WO2004058705 (CHEMOCENTRYX [US]) [I] 1-10,13-20 * claim 1 *; | [I]WO2007059108 (CHEMOCENTRYX INC [US], et al) [I] 1-10,13-20 * paragraph [0043]; claim 1 *; | [IP]WO2013190508 (ACTELION PHARMACEUTICALS LTD [CH]) [IP] 1-20* claim 1 * | by applicant | US3896170 | WO9942456 | WO0246164 | WO2009076404 | - SUN ET AL., "CXCL12/CXCR4/CXCR7 Chemokine Axis and Cancer Progression", CANCER METASTASIS REV., (2010), vol. 29, no. 4, pages 709 - 722 | - WANG ET AL., "The role of CXCR7/RDC1 as a chemokine Receptor for CXCL12/SDF-1 in prostate cancer", JOURNAL OF BIOCHEMICAL CHEMISTRY, (2008), vol. 293, no. 7, pages 4283 - 4294 | - EBSWORTH ET AL., "The effect of the CXCR7 inhibitor CCX662 on survival in the ENU rat model of gliobastoma", J CLIN ONCOL, (2012), vol. 30, page E13580 | - ZHENG ET AL., "Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells", JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH, (2010), vol. 29, page 31 | - MIAO ET AL., "CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor associated vasculature", PNAS, (2007), vol. 104, no. 40, pages 15735 - 15740 | - BURNS ET AL., "A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development", JOURNAL OF EXPERIMENTAL MEDICINE, (2006), vol. 203, no. 9, pages 2201 - 2213 | - WALTERS ET AL., "Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats", BRITISH JOURNAL OF CANCER, (2014), pages 1 - 10 | - CRUZ-ORENGO ET AL., "CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity", JOURNAL OF EXPERIMENTAL MEDICINE, (2011), vol. 208, no. 2, pages 327 - 339 | - SARTINA ET AL., "Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension", PEDIATRIC RESEARCH, (2012), vol. 71, no. 6, pages 682 - 688 | - WATANABE ET AL., "Pathogenic role of CXCR7 in rheumatoid arthritis", ARTHRITIS AND RHEUMATISM, (2010), vol. 62, no. 11, pages 3211 - 3220 | - DING ET AL., "Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis", NATURE, (2014), vol. 505, no. 7481, pages 97 - 102 | - IKEDA ET AL., "Modulation of Circadian Glucocorticoid Oscillation via Adrenal Opioid-CXCR7 Signaling Alters Emotional Behavior", CELL, (2013), vol. 155, no. 6, pages 1323 - 36 | - DUDA DG ET AL., CLIN CANCER RES, (2011), vol. 17, no. 8, pages 2074 - 80 | - BROWN BJ, SEMIN RADIAT ONCOL, (2013), vol. 23, no. 4, pages 281 - 7 | - KIOI ET AL., J CLIN INVEST, (2010), vol. 120, no. 3, pages 694 - 705 | - HATTERMANN ET AL., CANCER RESEARCH, (2010), vol. 70, no. 8, pages 3299 - 3308 | - HATTERMANN ET AL., ONCOLOGY REPORTS, (2012), vol. 27, pages 1348 - 1352 | - EBSWORTH ET AL., NEURO ONCOL, (2013), vol. 15, no. 3, pages III37 - III61 | - EBSWORTH ET AL., J CLIN ONCOL, (2012), vol. 30, page E13580 | - LIU SC ET AL., NEURO-ONCOLOGY, (2014), vol. 16, no. 1, pages 21 - 28 | - LIU SC ET AL., NEURO ONCOL, (2013), vol. 15, no. 3, pages III189 - III190 | - CALATOZZOLO C ET AL., CANCER BIOLOGY AND THERAPY, (2011), vol. 11, no. 2, pages 1 - 12 | - SALMAGGI ET AL., CANCER BIOLOGY AND THERAPY, (2009), vol. 8, no. 17, pages 1 - 7 | - IKEDA ET AL., CELL, (20131205), vol. 155, pages 1323 - 1336 | - CLIN. CANCER RES., (2011), vol. 17, no. 8, pages 2074 - 2080 | - NAUMANN ET AL., "CXCR7 function as a scavenger for CXCL1 2 and CXCL1 1", PLOS ONE, (2010), vol. 5, no. 2, page E9175 | - BIOORG. AND MED. CHEM. LETTERS, BIOORG. AND MED. CHEM. LETTERS, (2011), vol. 21, pages 1838 - 1843 | - J. MED. CHEM., (1990), vol. 33, no. 2, pages 596 - 600 | - J. MED. CHEM., (2012), vol. 55, pages 7746 - 7758 | - TETRAHEDRON, (2006), vol. 62, no. 29, pages 6869 - 6875 | - BIOORG. & MED. CHEM. LETTERS, (2006), vol. 16, no. 13, pages 3415 - 3418 |